Additionally, when the tumor clinicopathological state was evaluated, advanced BRCA patients (stage III and IV) showed significantly lower levels of GJB3—collectively suggesting that GJB3 promotes tumor-suppressive characteristics and may serve as a potential biomarker for both the detection and staging of breast cancer [26]. Here, GJB3 is linked to neoplasm.